|Systematic (IUPAC) name|
|Oral, Insufflation, Rectal|
|Molar mass||207.23 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
|Solubility in water||357 mg/mL (20 °C)|
Methylone, also known as "M1", 3,4-methylenedioxy-N-methylcathinone, bk-MDMA, and in the UK as Arlone, is an entactogen and stimulant of the phenethylamine, amphetamine, and cathinone classes. It was originally patented by Peyton Jacob and Alexander Shulgin in 1996 as an antidepressant. The more intuitive abbreviation MDMC unfortunately can not be used for this chemical, since it had already been given to another earlier Shulgin creation, 3,4-ethylenedioxymethamphetamine. Methylone is a close structural analogue of MDMA, differing by the addition of a β-ketone group.
At the end of 2004, a new designer drug called "Explosion" appeared in the Netherlands. This drug was sold as a liquid via the internet and in Dutch "smartshops" (known as "headshops" in the United States and some other countries), stores selling at the time non-scheduled, usually becoming illegal within a year of becoming well-known, psychoactive substances such as Salvia divinorum, Psilocybin mushrooms and other MDMA substitutes like BZP and TFMPP. The product is advertised as a "room odorizer" and is sold in plastic tubes containing 5 mL of liquid. The tubes cost between €10 and €15 ($13–$20) and do not present any information about the composition of Explosion; they contain only a label saying "Room odorizer Vanilla. Do not ingest" and "Keep away from children. Never use more than one bottle". Users have mentioned ingesting the liquid to reach euphoric stimulating effects similar to those of MDMA. The label circumvents Dutch regulations for illicit drugs and psychoactive substances when intentionally used for intoxication. Analysis of "Explosion" has confirmed that the active ingredient is methylone.
Reported dosages range from 100 to 250 mg orally. Some respondents say that increasing dose with methylone beyond 100-180mg causes increased physical effects and does not substantially improve the empathic cognitive effects.
The effects of methylone may include the following:
- Euphoria or dysphoria, and anxiolysis or anxiogenesis, depending on the individual.
- An increase in sociability and sexual behavior/hypersexuality
- Insomnia and restlessness
- Derealization/depersonalization, hallucinations, and psychosis, depending on the individual, and in all individuals with high dosage or extended use.
- Tachycardia and hypertension
- Hyperthermia and sweating
- Mydriasis and nystagmus
- Trismus and bruxism
- Nausea and vomiting
Most of these effects are very similar to those of other psychostimulants.
Resemblance to MDMA
Methylone resembles MDMA in its behavioural profile, as it substitutes for MDMA in rats trained to discriminate MDMA from saline. Methylone does not substitute for amphetamine or for the hallucinogenic DOM in animals trained to discriminate between these drugs and saline. Further, also in common with MDMA, methylone acts on monoaminergic systems. In vitro, methylone has one third the potency of MDMA at inhibiting platelet serotonin accumulation and about the same in its inhibiting effects on the dopamine and noradrenaline transporters.
In spite of these behavioural and pharmacological similarities between methylone and MDMA, the observed subjective effects of both drugs are not completely identical. Alexander Shulgin wrote of the former:
"[Methylone] has almost the same potency of MDMA, but it does not produce the same effects. It has an almost antidepressant action, pleasant and positive, but not the unique magic of MDMA."
Methylone acts as a mixed reuptake inhibitor/releasing agent of serotonin, norepinephrine, and dopamine. In comparison to MDMA, it has approximately 3x lower affinity for the serotonin transporter, while its affinity for the norepinephrine and dopamine transporters is similar. Notably, methylone's affinity for the vesicular monoamine transporter 2 (VMAT2) is about 13x lower than that of MDMA. The results of these differences in pharmacology relative to MDMA are that methylone is less potent in terms of dose, has more balanced catecholaminergic effects relative to serotonergic, and behaves more like a reuptake inhibitor like methylphenidate than a releaser like amphetamine; however, methylone has relatively robust releasing capabilities, perhaps due to its ability to phosphorylate the monoamine transporters being similar in potency relative to MDMA.
Little is currently known about the pharmacokinetics of methylone, aside from metabolism.
The two major metabolic pathways in mammals for methylone are N-demethylation to methylenedioxycathinone (MDC), and demethylation followed by O-methylation of the 3- or 4-hydroxy group to 4-hydroxy-3-methoxymethcathinone (HMMC) or 3-hydroxy-4-methoxymethcathinone (3-OH-4-MeO-MC). When 5 mg/kg of methylone was administered to rats, it was found that around 26% was excreted as HMMC within the first 48 hours (less than 3% excreted unchanged).
In the Netherlands, methylone is not yet scheduled as a drug of abuse, but is considered to be a psychoactive medicine. Because methylone is not registered officially, as such, it is forbidden to trade in methylone. The Minister of Health has asked the Coordination point Assessment and Monitoring new drugs group (CAM) to gather information about this substance, resulting possibly in an official risk assessment. Until now, no research has been conducted on the toxicity of methylone, so nothing is known about the harmfulness of this new drug.
Methylone is not a scheduled substance in the United States.
In New Zealand, although methylone is not explicitly scheduled and falls outside the strict definitions of an "amphetamine analogue" in the Misuse of Drugs Act, it is considered to be "substantially similar" to methcathinone and is thus considered by law enforcement authorities to be a Class C illegal drug.
In the UK, Methylone is illegal since the 16/04/2010 revision of the misuse of drugs act. Before this it was not specifically mentioned in United Kingdom (U.K.) law as the β-ketone was not covered under the Misuse of Drugs Act. In March 2010 plans were announced to make methylone and other cathinones, Class B drugs, "within weeks". While delayed by dissatisfaction in the [ACMD], the revision was rushed through by the government with little regard for the views of the ACMD. The importation of the compounds was banned immediately. Methylone was sold in New Zealand for around 6 months from November 2005 to April 2006 as an MDMA substitute, under the name "Ease". The product was withdrawn after legal disputes with the government.
In Sweden, methylone has been classed as a Harmful Substance since 2007, and with that sale and handling is restricted. The Harmful Substance Act (Förordning (1999:58) om förbud mot vissa hälsofarliga varor) is put in place as a step towards classing something as a narcotic, or as a substitute for that classification if it is deemed adequate enough. In Sweden the name in the books for the substance classified is 3,4-metylendioximetkatinon (Metylon).
"Methylone" is also a trademarked brand name for an injectable form of methylprednisolone, a corticosteroid hormone used to treat arthritis and severe allergic reactions; hence, methylone may be confused with it. Aside from context, they can be distinguished by the fact that the name will always be capitalized when referring to the prescription drug.
A proposed alternate name is bk-MDMA, or beta-keto-MDMA. While this nomenclature has not caught on because the name "methylone" became widely used before the conflicting Methylone trademark was noticed, the analogous names for related chemicals bk-MDEA and bk-MBDB have become the established names for those substances.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
- WO 9639133
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- TA Dal Cason, R Young, RA Glennon. Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol. Biochem. Behav. 58, 1109–1116 (1997)
- NV Cozzi, MK Sievert, AT Shulgin, P Jacob III, AE Ruoho. Methcathinone and 2 methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (methylone) selectively inhibit plasma membrane catecholamine reuptake transporters. Soc. Neurosci. Abs., 24, 341.8 (1998)
- NV Cozzi, AT Shulgin, AE Ruoho. Methcathinone (MCAT) and 2-methylamino-1-(3,4 methylenedioxyphenyl)propan-1-one (MDMCAT) inhibit [3H]serotonin uptake into human platelets. Amer. Chem. Soc. Div. Med. Chem. Abs., 215, 152 (1998)
- "Cathinone | Ask Dr. Shulgin Online".
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- Xenobioica. HT Kamata, N Shima, K Zaitsu, T Kamata, A Miki, M Nishikawa, M Katagi, H Tsuchihashi. (2006). Metabolism of methylone in humans and rats. Volume 36, Number 8 / August 2006.
- van Amsterdam et al., 2004
- "Suspected mephedrone-type compound seized at airport". BBC News. 1 April 2010. Retrieved 3 April 2010.
- Party pill sparks official concern. One News. April 7, 2006
- EASE trial terminated after conflicting advice. scoop.co.nz April 9, 2006
- "http://www.notisum.se/rnp/sls/lag/19990058.htm – Förordning (1999:58) om förbud mot vissa hälsofarliga varor". External link in